MARIA Alexandra BARBU

Dr. MARIA Alexandra BARBU

Institutul Oncologic Alexandru Trestioreanu, Bucharest, Bucureşti, Romania
+1
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 May 2018 in Romanian Journal of Internal Medicine
Verified
Journal Article
Open access
PDF file
MBMARIA Alexandra BARBU
MARIA Alexandra BARBU
CNCornelia Niţipir
Cornelia Niţipir
Theodor VoiosuTheodor Voiosu
Theodor Voiosu
CGCălin Giurcăneanu
Călin Giurcăneanu
Introduction. Skin toxicity in patients receiving novel therapeutic cancer agents has become a very important marker in determining drug activity, but it can also severely impact their quality of life. About half of the patients receiving this type of oncologic treatment will develop cutaneous reactions, that is why adequate understanding and management of these side effects is very important for drug adherence and patients’ quality of life. Materials and methods. We conducted a prospective study of consecutive patients who received oncologic treatment in our institution and presented with dermatologic side effects. The severity of skin toxicity was assessed using the DLQI score and patients were prospectively followed to evaluate response to therapy. Univariate analysis of factors influencing the impact of skin toxicity on patient QOL was conducted. Results. 52 patients were enrolled in the study. Patients who developed grade 3 and 4 skin toxicity had a higher DLQI score, with a greater impact on quality of life, but with better clinical outcome at 3 months follow-up, based on RECIST. Patients with moderate or severe cutaneous AE were more likely to achieve complete or partial response to therapy than those with mild AE (16/33 vs. 3/19, p = 0.035). Interestingly, female patients had a significantly poorer quality of life than male patients as assessed by the DLQI score (7.28 ± 7 vs. 3.7 ± 3.6, p = 0.038). Conclusion. Cutaneous side effects are often encountered in cancer patients and their severity can be a surrogate marker for a positive clinical tumor response to therapy.

10 May 2023 in Clinical Case Reports
Verified
Journal Article
Open access
MBMARIA Alexandra BARBU
MARIA Alexandra BARBU
RARodica Maricela Anghel
Rodica Maricela Anghel
GRGabriel Ricu
Gabriel Ricu
TTTiberiu Tebeica
Tiberiu Tebeica
RPRaluca Patru
Raluca Patru
AMAlexandru Michire
Alexandru Michire
Key Clinical Message: We report 2 cases of EPPER diagnosed in patients who received radiation therapy and hormonal therapy for locally advanced prostate cancer. Both our patients developed this rare late toxicity, but early diagnosis and treatment of this adverse event offers a good prognosis, with no unnecessary interruptions of oncological treatment required. Acute and late adverse events are a major problem for patients receiving radiation therapy. We describe two cases of eosinophilic, polymorphic, and pruritic eruption associated with radiotherapy (EPPER) syndrome, a very uncommon toxicity that affects cancer patients. Both our cases were men diagnosed with localized prostate cancer and were treated with radiotherapy and hormonal therapy. They developed EPPER during and after completing the total radiation dose. Multiple tests and skin biopsies were performed in order to find a superficial perivascular lymphohistiocytic infiltrate, confirming EPPER. The patients received corticotherapy and fully recovered after this treatment. There are a few more cases of EPPER reported in the literature, but the pathogenic mechanism is still unknown. EPPER is an important side effect of radiation therapy and it is probably underdiagnosed, due to its occurrence (usually after completing the oncological treatment).

26 August 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MBMARIA Alexandra BARBU
MARIA Alexandra BARBU
MGMiruna Ghigeanu
Miruna Ghigeanu
SBSarah Bahaa-Eddin
Sarah Bahaa-Eddin
MAMichire Alexandru
Michire Alexandru
AHAlexandra Hanu
Alexandra Hanu
MGMihai Teodor Georgescu
Mihai Teodor Georgescu
Background: Cervical cancer is considered to be a global health challenge, particularly in low- and middle-income countries. Romania reports one of the highest burdens in Europe due to limited access to screening and HPV vaccination. Chemoradiotherapy is standard for locally advanced disease, but the impact on quality of life (QoL) for a low- and middle-income population has not yet been explored. This study aims to evaluate the effect of chemoradiotherapy on the QoL of cervical cancer survivors in the Romanian population. Methods: This prospective observational study included 111 patients with stage I–IV cervical cancer undergoing chemoradiotherapy. QoL was assessed using the Functional Assessment of Cancer Therapy-General (FACT-G) questionnaire before, during, and after treatment. Demographic and clinical data were collected. The statistical analyses included t-tests, ANOVA, and linear mixed-effects models to evaluate changes over time and the influence of sociodemographic and treatment-related factors. Results: FACT-G scores significantly increased after treatment, with improvements in physical and functional well-being. Better before-treatment QoL was associated with urban residence, early-stage disease, marital status, and higher education. Among treatment toxicities, only nausea had a statistically significant negative effect on QoL during treatment, while other toxicities showed no significant impact. Conclusions: Chemoradiotherapy in cervical cancer patients was not associated with a substantial deterioration in quality of life during treatment and was followed by significant improvement after therapy completion. These findings highlight a favorable short-term QoL trajectory and emphasize the need for longitudinal studies to assess whether such benefits are maintained over the long term.

3 November 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
IPIleana-Raluca Pătru
Ileana-Raluca Pătru
AAAlexandra Valentina Anghel
Alexandra Valentina Anghel
EGEusebiu Robert Galeschi
Eusebiu Robert Galeschi
LBLorena Carolina Bataus
Lorena Carolina Bataus
Miron Andreea IulianaMiron Andreea Iuliana
Miron Andreea Iuliana
Ionut-Lucian Antone-IordacheIonut-Lucian Antone-Iordache
Ionut-Lucian Antone-Iordache
Background: Immunotherapy with immune checkpoint inhibitors (ICIs) has fundamentally transformed cancer treatments. Unfortunately, its benefits are accompanied by the occurrence of immune-related adverse events (irAEs). While non-cardiac irAEs have been consistently associated with a favorable prognosis, the impact of cardiac toxicities remains insufficiently explored. Methods: We conducted a retrospective, observational study at the Oncology Department of Colțea Clinical Hospital, Bucharest. All the patients treated with ICIs between 1 May 2019 and 1 February 2024 were selected in the initial cohort. Of 512 eligible patients, 435 were included in the final analysis, with comprehensive recordings of clinical, oncological, and cardiac monitoring parameters, and at least one complete cycle of ICI treatment. Adverse events were classified according to CTCAE v5.0, and overall survival (OS) and progression-free survival (PFS) were assessed using Kaplan–Meier estimates and Cox regression models. Results: Our results showed that patients who developed non-cardiac irAEs experienced a significant survival benefit: median OS 26.0 months (95% CI, 15.5–NA) vs. 13.9 months (95% CI, 12.4–16.5), 0.66 (95% CI, 0.49–0.9) hazard ratio (HR); median PFS 12.3 months (95% CI, 8.1–26.0) vs. 8.7 months (95% CI, 7.3–10.3), 0.74 (95% CI, 0.56–0.97) HR. Conversely, patients with cardiac toxicities did not derive the same advantage, with similar OS and PFS values that did not reach statistical significance: median OS 15.0 months (95% CI, 13.3–19.3) vs. 15.8 months (95% CI, 12.0–30.3), 1.11 (95% CI, 0.78–1.57) HR; median PFS 9.1 months (95% CI, 7.6–10.4) vs. 8.1 months (95% CI, 5.3–19.3), 1.003 (95% CI, 0.72–1.39) HR. Conclusions: These findings support the role of non-cardiac irAEs as markers of favorable therapeutic response, while cardiac irAEs do not confer the same prognostic benefit. The results underscore the importance of active cardiovascular monitoring and close multidisciplinary collaboration in the management of patients receiving ICIs.

29 April 2022 in Gastrointestinal Disorders
Verified
Journal Article
Open access
PDF file
MAMichire Alexandru
Michire Alexandru
RARodica Maricela Anghel
Rodica Maricela Anghel
PDPetruta Maria Draghia
Petruta Maria Draghia
MBMihnea Gabriel Burlacu
Mihnea Gabriel Burlacu
TGTeodor Florin Georgescu
Teodor Florin Georgescu
AGAlexandra Gaube
Alexandra Gaube
Colorectal cancer (CRC) is one of the most common cancers and represents a major global health burden. While genetics are implicated in a portion of CRC patients, most cases are sporadic. A new possibility of tumor initiation and promotion might be microbiome composition. It was recently shown that bacteria from the gut microbiome might be used as biomarkers for CRC detection, especially Fusobacterium nucleatum, Peptostreoptococcus stomatis, Parvimonas mica, Solobacterium moorei, and Peptostreptococcus anaerobius. Conversely, the healthy gut microbiome is mostly colonized by Bacterioides (Bacterioides fragilis, vulgatus, uniformis), Firmicutes (Clostridium spp., Ruminococcus faecis, Enterococcus faecium), and Actinobacteria (Bifidobacterium bifidum). Some strains of gut bacteria favor tumor promotion through DNA and RNA damage (directly or through interaction with other known food carcinogens) and through local immune inhibition. It is possible that bacteria (e.g., Bacillus polyfermenticus, Alistipes shahii, Lactobacillus casei) exist with protective functions against tumor promotion. Despite current advances in colorectal cancer treatment, especially in the medical oncology and radiotherapy domains, surgery remains the mainstay of curative treatment for colorectal cancer patients, even in the oligometastatic setting. Surgical complications like anastomotic leakage, excessive blood loss, abscess, and abdominal sepsis can reduce 1-year and 5-year overall survival and increase the recurrence rates for these patients; therefore, we reviewed currently published data focusing on the relationship between gut microbiota and postoperative complications for colorectal cancer patients.

Verified
Journal Article
Open access
PDF file
RRRahnea Nita Roxana
Rahnea Nita Roxana
LRLaura –Florentina Rebegea
Laura –Florentina Rebegea
Elena Gabriela ValcuElena Gabriela Valcu
Elena Gabriela Valcu
MDMihaela Emilia Dumitru
Mihaela Emilia Dumitru
RTRADU VALERIU TOMA
RADU VALERIU TOMA
GRGabriela I Rahnea-Nita
Gabriela I Rahnea-Nita
Introduction. Anxiety and depression have an increased prevalence in cancer patients, especially in those in an advanced stage of the disease. These disorders have a major impact on the social life, existential concerns and quality of life of cancer patients. Materials and Methods. A number of 114 consecutive patients were included in the study (in a period of 2 weeks) who were screened for anxiety, depression and for other common symptoms, using Hospital Anxiety and Depression Scale (HADS) and Edmonton Symptom Assessment System (ESAS). Results. Regarding the age—the abnormal level of anxiety and depression: the percentage of patients over 65 years was higher than the percentage of patients under 64 years, both in terms of anxiety and depression. Regarding the Performance status ECOG—abnormal level of anxiety and depression: the percentage of patients with ECOG = 3–4 is higher than that of patients with ECOG = 0–2. Results. The increased prevalence of anxiety and depression requires psychological counseling and treatment. It is important for these symptoms to be identified as soon as possible, in order to provide a good quality of life. Conclusions. The model we propose is for the HADS to be a screening tool on admission to a palliative care ward, for certain categories of patients.